Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

ceived from Ortho-McNeil-Janssen in 2007 is fully amortized in the third quarter of this year.

Operating Expenses

On a pro forma basis, operating expenses for the three and six months ended June 30, 2009 were $32.3 million and $61.8 million compared to $25.1 million and $46.4 million for the same periods in 2008. Consistent with Isis' guidance, the higher expenses in 2009 were primarily due to the expansion of the Company's clinical development programs, including additional expenses associated with the broad Phase 3 clinical program for mipomersen, the lead drug in Isis' cardiovascular franchise, expenses for Regulus as it builds its core team and expenses related to the Company's expansion of its drug discovery activities into new therapeutic areas. On a GAAP basis, Isis' operating expenses from continuing operations for the three and six months ended June 30, 2009 were $35.8 million and $68.0 million compared to $28.6 million and $53.2 million for the same periods in 2008, including non-cash compensation expense related to stock options of $3.6 million and $6.3 million for the three and six months ended June 30, 2009 and $3.5 million and $6.8 million for the same periods in 2008. During the remainder of 2009, Isis' operating expenses will increase modestly as Isis continues its research and development activities described above.

Interest Expense

In 2009, Isis adopted FASB Staff Position No. APB 14-1 (FSP 14-1) for its 2 5/8% convertible notes, which required Isis to assign a value to its convertible debt without considering the conversion feature. As a result, Isis is recording its convertible debt at a discount, which Isis is amortizing over the expected life of the debt as additional non-cash interest expense. FSP 14-1 required retrospective application to all periods presented. Accordingly, the amount of interest expense Isis recorded in its statement of ope
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... been named the 2013 Life Science Firm of the Year ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders and ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
(Date:5/23/2013)...  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), ... on intellectual property developed and owned by Hadassah ... medical research center, today announced that its portfolio ... from the Israeli Ministry of Industry and Commerce, ... product development and advance clinical trials. Cell Cure,s ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... DETROIT , March 11 Caraco ... launched oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, ... approval from the US Food and Drug Administration (FDA) ... is an anticancer used in the treatment of colon ...
... today the commercial launch of its new VivoTag ® 680 XL fluorescent dye for labeling biomolecules in a broad range of ... ... ... ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 3VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 2VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 3VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 4
(Date:5/24/2013)... Wednesday, 15th May 2013 | 10am BST | 5pm ... playback: http://bit.ly/10Rt0ZH , Ongoing regulatory changes are likely ... globe and particularly in Europe, a number of these new ... For dealmakers, understanding how the likes of Basel iii, Solvency ... corner of the market will give you a competitive edge ...
(Date:5/24/2013)... 2013 HCG EZ Drops has been ... to announce it’s new weight loss initiative. “We are so confident ... our customers their money back if they don’t lose 21 pounds ... EZ Drops. “The HCG Diet consists of 21 days of ... in 21 days.” , The controversial, cutting-edge diet has been hailed ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The leading retail ... discount offer on short prom dresses . Now that ... that is standard with the brand name since its origin. ... in prom dresses. And now this huge discount offer will ... “I feel highly privileged to announce that Short ...
(Date:5/23/2013)... Los Angeles, CA (PRWEB) May 23, 2013 ... healthcare delivery has been gradually transforming, which has affected ... by medical school debt and seeking regular hours, more ... instead joining hospitals or other medical groups,” says IBISWorld ... operating costs and reimbursement pressure, a number of older ...
(Date:5/23/2013)... PHILADELPHIA, May 24, 2013 -- High blood glucose is ... of intensive insulin therapy (IIT) to control hyperglycemia is ... does not show a consistent benefit and even shows ... the American College of Physicians, (ACP) Clinical Guidelines Committee ... the American Journal of Medical Quality . , ...
Breaking Medicine News(10 mins):Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2
... readmitted within a year, study finds , , WEDNESDAY, April ... discharged from the hospital is readmitted within 30 days, ... a year, a new study finds. , The groundbreaking ... that researchers believe could be prevented through better care ...
... Calif., April 1, 2009 UC Irvine pharmacological researchers ... regulation can limit cocaine cravings. Their findings could herald ... Shinjae Chung and Olivier Civelli, the study identified how ... "pleasure center" to create an addictive response to cocaine ...
... NVAX) announced today that it has ... common stock at $0.88 per share to a wholly owned subsidiary ... Novavax and Cadila. Novavax intends to use the $11 million in ... 4.75% senior convertible notes due in July 2009 and for a ...
... April 1 Medicare beneficiaries who need physical ... efficient to obtain treatment under legislation introduced yesterday ... Patient Access to Physical Therapists Act (HR 1829), ... (R-PA), and Tammy Baldwin (D-WI), eliminates the need ...
... AILA believes this reform must include a rational model for giving American ... that can open the door to innovation and international markets. , ... ... fuel to speed it to recovery. And, once recovered, it ...
... April 1 On April 1st, Professional Healthcare Resources ... patients in their homes. The company was started in ... and has grown to an organization offering home health, ... of Columbia, and Virginia. The company has over 700 ...
Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:UCI researchers find new way to fight cocaine addiction 2Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 3Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 2Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 3Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
... is the first truely web-based solution on the ... POC (managed from the lab) and Critical Care ... of AegisPOC ensures that all groups have the ... in the manner best suited to them. Through ...
...
... The Vari-Lase Endovenous Laser System is ... for varicose veins in the leg. Endovenous ... surgical vein-stripping for the treatment of varicose ... laser fiber is inserted into the varicosed ...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
Medicine Products: